127 related articles for article (PubMed ID: 12081731)
1. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma.
Jenkins GJ; Doak SH; Parry JM; D'Souza FR; Griffiths AP; Baxter JN
Br J Surg; 2002 Jul; 89(7):824-37. PubMed ID: 12081731
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations in Barrett's esophagus and esophageal adenocarcinoma.
Dinjens WN
Minerva Chir; 2002 Dec; 57(6):733-52. PubMed ID: 12592217
[TBL] [Abstract][Full Text] [Related]
3. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
[TBL] [Abstract][Full Text] [Related]
4. Dedifferentiation precedes invasion in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Helm J; Enkemann SA; Coppola D; Barthel JS; Kelley ST; Yeatman TJ
Clin Cancer Res; 2005 Apr; 11(7):2478-85. PubMed ID: 15814623
[TBL] [Abstract][Full Text] [Related]
5. The molecular biology of esophageal adenocarcinoma.
Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
[TBL] [Abstract][Full Text] [Related]
6. 3p21, 5q21, 9p21 and 17p13.1 allelic deletions are potential markers of individuals with a high risk of developing adenocarcinoma in Barrett's epithelium without dysplasia.
Sanz-Ortega J; Hernández S; Saez MC; Sierra E; Sanz-Ortega G; Torres A; Balibrea JL; Sanz-Esponera J; Merino MJ
Hepatogastroenterology; 2003; 50(50):404-7. PubMed ID: 12749233
[TBL] [Abstract][Full Text] [Related]
7. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus.
Barrett MT; Sanchez CA; Galipeau PC; Neshat K; Emond M; Reid BJ
Oncogene; 1996 Nov; 13(9):1867-73. PubMed ID: 8934532
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal instability in Barrett's esophagus is related to telomere shortening.
Finley JC; Reid BJ; Odze RD; Sanchez CA; Galipeau P; Li X; Self SG; Gollahon KA; Blount PL; Rabinovitch PS
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1451-7. PubMed ID: 16896031
[TBL] [Abstract][Full Text] [Related]
9. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
[TBL] [Abstract][Full Text] [Related]
10. Molecular genetic analysis of surveillance biopsy samples from Barrett's mucosa--significance of sampling.
Werther M; Saure C; Pahl R; Schorr F; Rüschoff J; Alles JU; Heinmöller E
Pathol Res Pract; 2008; 204(5):285-94. PubMed ID: 18337019
[TBL] [Abstract][Full Text] [Related]
11. [Oncogene amplification and genetic heterogeneity in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett esophagus].
Walch A; Bink K; Hutzler P; Zitzelsberger H; Braselmann H; Aubele M; Höfler H; Werner M
Verh Dtsch Ges Pathol; 2001; 85():257-63. PubMed ID: 11894407
[TBL] [Abstract][Full Text] [Related]
12. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
[TBL] [Abstract][Full Text] [Related]
13. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
14. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations.
Hardie LJ; Darnton SJ; Wallis YL; Chauhan A; Hainaut P; Wild CP; Casson AG
Cancer Lett; 2005 Jan; 217(2):221-30. PubMed ID: 15617840
[TBL] [Abstract][Full Text] [Related]
15. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy.
Blount PL; Galipeau PC; Sanchez CA; Neshat K; Levine DS; Yin J; Suzuki H; Abraham JM; Meltzer SJ; Reid BJ
Cancer Res; 1994 May; 54(9):2292-5. PubMed ID: 8162566
[TBL] [Abstract][Full Text] [Related]
16. Advances in gene chip technique in Barrett's metaplasia and adenocarcinoma.
Wang XW; Gao HJ; Fang DC
J Dig Dis; 2008 May; 9(2):68-71. PubMed ID: 18419638
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology of Barrett's adenocarcinoma.
Wijnhoven BP; Tilanus HW; Dinjens WN
Ann Surg; 2001 Mar; 233(3):322-37. PubMed ID: 11224619
[TBL] [Abstract][Full Text] [Related]
18. [Morphology and biology of invasion with Barret's carcinoma as an example].
Werner M; Walch A
Verh Dtsch Ges Pathol; 2000; 84():62-8. PubMed ID: 11217450
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression.
Doak SH; Jenkins GJ; Parry EM; Griffiths AP; Baxter JN; Parry JM
Mutat Res; 2004 Mar; 547(1-2):133-44. PubMed ID: 15013707
[TBL] [Abstract][Full Text] [Related]
20. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
